Safety and tolerability of antipsychotic polypharmacy

Expert Opinion on Drug Safety

Volumn 11, Issue 4, 2012, Pages 527-542

  Gallego, Juan A ^a,f   Nielsen, Jimmi ^b   De Hert, Marc ^c   Kane, John M ^a,d,e,f   Correll, Christoph U ^a,d,e,f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Adverse effects; Anticholinergic medications; Antipsychotic; Drugdrug interaction; EPS; Glucose abnormalities; Mortality; Polypharmacy; Sedation; Weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FOLLITROPIN; GLUCOSE; GONADORELIN; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIPRASIDONE;

ADD ON THERAPY; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BIPOLAR DISORDER; BODY MASS; COGNITIVE DEFECT; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; ILEUS; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PARKINSONISM; POLYPHARMACY; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; HUMANS; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; POLYPHARMACY; WEIGHT GAIN;

EID: 84862880757     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.683523     Document Type: Article

References (113)

1. Stahl SM. Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry 2002;63:93-4
2. Baandrup L, Sorensen J, Lublin H, et al. Association of antipsychotic polypharmacy with health service cost: A register-based cost analysis. Eur J Health Econ 2011 Mar 31. [Epub ahead of print] PubMed PMID:21452062
3. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11
4. Nielsen J, le Quach P, Emborg C, et al. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122:356-66
5. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32
6. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57
7. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009;35:458-68
8. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-7
9. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and metaregression of global and regional trends from the 1970s to 2009. Schizophr Res; in press
10. Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 2011;[Epub ahead of print] PubMed PMID:21419603
11. Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-21
12. Iqbal N, Lambert T, Masand P. Akathisia: problem of history or concern of today. CNS Spectr 2007;12:1-13
13. Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986;88:403-19
14. Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010;44:1171-80
15. Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: A review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010;71:566-73
16. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007;40:47-52
17. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007;58:489-95
18. Megna JL, Kunwar AR, Mahlotra K, et al. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 2007;13:129-37
19. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-101
20. Carnahan RM, Lund BC, Perry PJ, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006;113:135-41
21. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88
22. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9
23. Taylor D, Mace S, Mir S, et al. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000;4:41-6
24. Florez Menendez G, Blanco Ramos M, Gomez-Reino Rodriguez I, et al. Polipharmacy in the antipsychotic prescribing in practices psychiatric out-patient clinic. Actas Esp Psiquiatr 2004;32:333-9
25. Mason AS, Nerviano V, DeBurger RA. Patterns of antipsychotic drug use in four Southeastern state hospitals. Dis Nerv Syst 1977;38:541-5
26. Clark A, Holden N. the persistence of prescribing habits: A survey and follow-up of prescribing to chronic hospital in-patients. Br J Psychiatry 1987;150:88
27. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58:178-83
28. Kiivet RA, Llerena A, Dahl ML, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995;40:467-76
29. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Eur J Clin Pharmacol 1999;55:685-90
30. De Hert M, Wampers M, Peuskens J. Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract 2006;10:285-90
31. De Hert M, Wampers M, van Winkel R, et al. Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 2007;152:165-72
32. Hanssens L, De Hert M, Wampers M, et al. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemol Ment Health 2006;2:11
33. Lin CH, Kuo CC, Chou LS, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol 2010;30:518-25
34. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348-57
35. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-7
36. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(Suppl 4):5-9
37. Tsai G, Goff DC, Chang RW, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-13
38. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6
39. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204
40. Petty RG. Prolactin and antipsychotic medications: Mechanism of action. Schizophr Res 1999;35(Suppl):S67-73
41. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: Association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004;65:1491-8
42. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: Impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-8
43. Anil YAE, Kivircik ABB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63
44. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73
45. Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial. J Psychopharmacol 2009;23:305-14
46. Kuwilsky A, Krumm B, Englisch S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20.PubMed PMID:20589598
47. Shores LE. Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Psychiatry (Edgmont) 2005;2:42-5
48. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: A switching or add-on study. J Psychopharmacol 2008;22:244-53
49. Chen CK, Huang YS, Ree SC, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1495-9
50. Yasui-Furukori N, Furukori H, Sugawara N, et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010;30:596-9
51. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry 2007;164:1404-10
52. Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007;20:138-42
53. Brooks JO III, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry 2011;72:240-7
54. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;Oct 18;8(2):114-26; doi: 10.1038/nrendo.2011.156. PubMed PMID: 22009159
55. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011;17:97-107
56. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20:368-78
57. Kim SF, Huang AS, Snowman AM, et al. From the cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456-9
58. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62(Suppl 23):23-9
59. Sussman N. the implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003;23:S21-6
60. Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008;49:65-9
61. Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008;23:283-90
62. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Investig 1999;18:99-104
63. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;21:453-6
64. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: An open clinical study. Clin Neuropharmacol 2005;28:220-4
65. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-7
66. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13:1115-25
67. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009;29:165-9
68. Henderson DC, Fan X, Copeland PM, et al. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009;24:225-32
69. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-31
70. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82
71. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73
72. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52
73. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-71
74. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100
75. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011;11:118
76. Krane-Gartiser K, Breum L, Glumrr C, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011;65:345-52
77. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ J Psychiatry 2007;41:606-10
78. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-13
79. Taylor D, Young C, Esop R, et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;185:152-6
80. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23:215-28
81. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5:97-104
82. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
83. Ramos-Rios R, Arrojo-Romero M, Paz-Silva E, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res 2010;116:35-43
84. Correll CU, Frederickson AM, Figen V, et al. the QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2009;259:23-7
85. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. J Clin Psychiatry 2005;66:1386-91
86. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9
87. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009;374:620-7
88. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6
89. Barbui C, Nose M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006;21:355-62
90. Ganesan S, Taylor R, Rabheru K, et al. Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr Res 2008;98:323-4
91. Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6:3-7
92. Ziegenbein M, Sieberer M, Calliess IT, et al. Combination of clozapine and aripiprazole: A promising approach in treatment-resistant schizophrenia. Aust NZ J Psychiatry 2005;39:840-1
93. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: Three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1167-9
94. Nielsen J, Meyer JM. Risk Factors for Ileus in Patients with Schizophrenia. Schizophr Bull 2010 Nov 26. [Epub ahead of print] PubMed PMID: 21112965
95. Vinogradov S, Fisher M, Warm H, et al. the cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009;166:1055-62
96. Sweeney JA, Keilp JG, Haas GL, et al. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991;37:297-308
97. Elie D, Poirier M, Chianetta J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010 Jul;24(7):1037-44. Epub 2009 Jan 22, PubMed PMID: 19164494
98. Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006;86:138-46
99. Kontis D, Theochari E, Kleisas S, et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1333-41
100. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother 2000;34:662-5
101. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992;May;(17):54-9. PubMed PMID: 1358128
102. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006;21:99-103
103. Husain Z, Almeciga I, Delgado JC, et al. Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 2006;214:326-34
104. Lander M, Bastiampillai T. Neutropenia associated with quetiapine, olanzapine, and aripiprazole. Aust NZ J Psychiatry 2011;45:89
105. Ebert MH, Shader RI. Hepatic effects. In: Shader RI, DiMasccio A, editors. Psychotropic Drug Side Effects. Williams and Wilkins Co.; Baltimore: 1970. p. 175-97
106. Atasoy N, Erdogan A, Yalug I, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255-60
107. Hummer M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17:314-17
108. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81
109. Suzuki T, Uchida H, Watanabe K, et al. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:361-9
110. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011;168:702-8
111. Kuwilsky A, Krumm B, Englisch S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20
112. Goren JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008;34:571-82
113. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23